{
    "doi": "https://doi.org/10.1182/blood.V122.21.253.253",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=2493",
    "start_url_page_num": 2493,
    "is_scraped": "1",
    "article_title": "Optimizing Early Prediction Of Outcome In CML Using The Exact Decline Of BCR-ABL Transcript Levels Within 3 Months Of Imatinib Treatment As a Prognostic Marker ",
    "article_date": "November 15, 2013",
    "session_type": "632. Chronic Myeloid Leukemia: Therapy",
    "topics": [
        "bcr-abl tyrosine kinase",
        "imatinib mesylate",
        "prognostic marker",
        "brachial plexus neuritis",
        "hydroxyurea",
        "beta-glucuronidase",
        "follow-up",
        "leukemia, myeloid, chronic-phase",
        "phlebotomy",
        "predictive marker"
    ],
    "author_names": [
        "Benjamin Hanfstein, MD",
        "Valeria Shlyakhto",
        "Michael Lauseker",
        "R\u00fcdiger Hehlmann, MD",
        "Susanne Saussele, MD",
        "Philipp Erben, MD",
        "Christian Dietz, PhD",
        "Alice Fabarius, PhD",
        "Ulrike Proetel, MD",
        "Susanne Schnittger, PhD",
        "Stefan W. Krause, MD",
        "J\u00f6rg Schubert, MD",
        "Hermann Einsele, MD",
        "Mathias H\u00e4nel, MD",
        "Jolanta Dengler, MD",
        "Christiane Falge, MD",
        "Lothar Kanz, MD",
        "Andreas Neubauer, MD",
        "Michael Kneba, MD",
        "Frank Stegelmann, MD",
        "Michael Pfreundschuh, MD",
        "Cornelius F. Waller, MD",
        "Karsten Spiekermann, MD",
        "Gabriela M. Baerlocher, MD",
        "Markus Pfirrmann, PhD",
        "Joerg Hasford, MD",
        "Wolf-Karsten Hofmann, MD",
        "Andreas Hochhaus, MD",
        "Martin C. M\u00fcller, MD"
    ],
    "author_affiliations": [
        [
            "III. Medizinische Klinik, Universit\u00e4tsmedizin Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Universit\u00e4tsmedizin Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany, "
        ],
        [
            "Institut f\u00fcr Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany, "
        ],
        [
            "III. Medizinische Klinik, Universit\u00e4tsmedizin Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Universit\u00e4tsmedizin Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Universit\u00e4tsmedizin Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Universit\u00e4tsmedizin Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Universit\u00e4tsmedizin Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Universit\u00e4tsmedizin Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany, "
        ],
        [
            "MLL M\u00fcnchner Leuk\u00e4mielabor, M\u00fcnchen, Germany, "
        ],
        [
            "Medizinische Klinik 5, Universit\u00e4tsklinikum, Erlangen, Germany, "
        ],
        [
            "Klinik f\u00fcr H\u00e4matologie, Onkologie und Palliativmedizin, Evangelische Krankenhaus, Hamm, Germany, "
        ],
        [
            "Medizinische Klinik und Poliklinik II, Universit\u00e4tsklinikum, W\u00fcrzburg, Germany, "
        ],
        [
            "Klinik f\u00fcr Innere Medizin III, Klinikum, Chemnitz, Germany, "
        ],
        [
            "Innere Medizin V, Universit\u00e4tsklinikum, Heidelberg, Germany, "
        ],
        [
            "Medizinische Klinik 5, Klinikum Nord, N\u00fcrnberg, Germany, "
        ],
        [
            "Innere Medizin II, Universit\u00e4tsklinikum, T\u00fcbingen, Germany, "
        ],
        [
            "Klinik f\u00fcr Innere Medizin, Schwerpunkt H\u00e4matologie, Onkologie und Immunologie, Universit\u00e4tsklinikum, Marburg, Germany, "
        ],
        [
            "II. Medizinische Klinik und Poliklinik im St\u00e4dtischen Krankenhaus, Universit\u00e4tsklinikum Schleswig-Holstein, Kiel, Germany, "
        ],
        [
            "Klinik f\u00fcr Innere Medizin III, Universit\u00e4tsklinikum, Ulm, Germany, "
        ],
        [
            "Klinik f\u00fcr Innere Medizin I, Universit\u00e4tsklinikum des Saarlandes, Homburg/Saar, Germany, "
        ],
        [
            "Klinik f\u00fcr Innere Medizin I, Universit\u00e4tsklinikum, Freiburg, Germany, "
        ],
        [
            "Medizinische Klinik und Poliklinik III, Klinikum der Universit\u00e4t, M\u00fcnchen, Germany, "
        ],
        [
            "Universit\u00e4tsklinik f\u00fcr H\u00e4matologie und h\u00e4matologisches Zentrallabor, Inselspital, Bern, Switzerland, "
        ],
        [
            "Institut f\u00fcr Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany, "
        ],
        [
            "Institut f\u00fcr Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany, "
        ],
        [
            "III. Medizinische Klinik, Universit\u00e4tsmedizin Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany, "
        ],
        [
            "Klinik f\u00fcr Innere Medizin II, Abt. H\u00e4matologie und Intern. Onkologie, Universit\u00e4tsklinikum, Jena, Germany"
        ],
        [
            "III. Medizinische Klinik, Universit\u00e4tsmedizin Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany, "
        ]
    ],
    "first_author_latitude": "49.49235225",
    "first_author_longitude": "8.486776949999998",
    "abstract_text": "Introduction Early assessment of BCR-ABL transcript levels at 3 months allows the prediction of survival and may serve as a trigger for treatment intensification in CML patients with slow response to imatinib. The exact decline of BCR-ABL transcript levels within the first 3 months of treatment is defined by the ratio BCR-ABL transcripts at 3 months to BCR-ABL transcripts at baseline. This ratio might better reflect the individual biology of disease and its susceptibility to tyrosine kinase inhibition. Methods A total of 408 chronic phase CML patients (pts) with baseline and 3 month blood samples available in one single laboratory were investigated. Pts with pre-treatment before first blood sampling were excluded (imatinib with or without hydroxyurea, n=58; hydroxyurea only, n=49). A total of 301 evaluable pts (median age 52 years, range 18-85, 41% female) were treated with an imatinib-based therapy within the CML-Study IV. Median follow-up was 4.8 years. Transcript levels of BCR-ABL, total ABL, and beta-glucuronidase (GUS) were determined by quantitative RT-PCR. Exploratory landmark analyses were performed with regard to overall and progression-free survival (OS, PFS) to evaluate the prognostic significance of (i) BCR-ABL/GUS before treatment, (ii) the individual reduction of transcripts given by (BCR-ABL/GUS at 3 months) / (BCR-ABL/GUS before treatment), and (iii) the 3-month 10% BCR-ABL IS landmark. Results The median BCR-ABL/GUS ratio was 15.5% at diagnosis (0.06-107) and 0.63% at 3 months (0-84) reflecting a decline to the 0.04-fold (1.4 log reduction). i) No prognostic cut-off could be identified for BCR-ABL/GUS before treatment. ii) A reduction to the 0.35-fold of the initial BCR-ABL transcript level at diagnosis (0.46 log reduction) was identified as best cut-off according to a hazard ratio of 5.6 (95%-CI 2.3-13.4, p<0.001 for PFS). Using this cut-off a high-risk group of 48 pts (16% of pts, 5-year PFS and OS: 77% and 83%) was separated from a good-risk group of 253 pts (84% of pts, 5-year PFS and OS: 96% and 98%). iii) As a comparison we investigated the 10% BCR-ABL IS landmark at 3 months with a hazard ratio of 2.4 (95%-CI 1.0-5.8, p=0.06 for PFS). With this landmark a high-risk group of 67 pts (22% of pts, 5-year PFS and OS: 87% and 90%) was separated from a good-risk group of 234 pts (78% of pts, 5-year PFS and OS: 95% and 97%). Conclusion A two-group risk stratification according to the individual reduction of BCR-ABL transcripts to the 0.35-fold of pre-treatment levels yields a superior separation of risk groups with a 5-year difference of 19% for PFS and 15% for OS. This predictive marker might identify patients at risk more precisely than 3-month 10% BCR-ABL IS . Disclosures: Hehlmann: BMS: Consultancy, Research Funding; Novartis: Research Funding. Saussele: Novartis: Honoraria, Research Funding, Travel Other; BMS: Honoraria, Research Funding, Travel, Travel Other; Pfizer: Honoraria. Hochhaus: Novartis: Consultancy, Honoraria, Research Funding, Travel Other; BMS: Consultancy, Honoraria, Research Funding; ARIAD: Consultancy, Honoraria; Pfizer: Consultancy. M\u00fcller: Novartis: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Ariad: Consultancy, Honoraria, Research Funding."
}